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 Introduction 
 Merkel cell carcinoma (MCC) is a rare aggressive neu-
roendocrine malignancy that frequently shows local re-
currence, lymph node and distant metastases. One hy-
pothesis claims that it derives from the normal Merkel 
cells of the epidermis which are slow-adapting mechano-
receptors. It was first described in 1972 by Toker  [1] who 
identified five patients with unusual skin tumors. Within 
the last 20 years its incidence has tripled, with an 8% an-
nual increase rate  [2] , leading the American Cancer soci-
ety to predict approximately 1,500 new MCC cases in 
2008  [3] . It occurs on sun-exposed skin areas in the Cau-
casian population, predominantly males, with a mean 
age at the time of diagnosis of 70 years  [4] . Its incidence 
rate rises with immunosuppression, e.g. in organ trans-
plant recipients, as well as in those with chronic lympho-
cytic leukemia and HIV infection  [5–7] . This link to im-
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 Abstract 
 Background: Merkel cell carcinoma (MCC) is a malignant 
neuroendocrine neoplasm which shares structural and im-
munohistochemical features with neuroectodermally de-
rived cells. One hypothesis claims that it arises from Merkel 
cells, highly innervated neuroendocrine cells involved in 
mechanoreception in the skin. The incidence rate of this can-
cer increases with age and sun exposure as well as after im-
munosuppression. Recently, the clonal integration of a new-
ly identified polyomavirus called Merkel cell polyomavirus 
(MCPyV) was reported in up to 80% of MCC tissue. Here we 
report the incidence rate of MCPyV in MCC patients in Swit-
zerland. Methods: We performed polymerase chain reaction 
in a collection of 32 samples obtained from pathology insti-
tutes around Switzerland. We used three different published 
primer sets. As control groups we used 7 squamous cell car-
cinoma samples and 11 normal skin samples.  Conclusions: 
We detected viral DNA in 20 out of 30 cases of MCC and in 0 
out of 19 control samples. The presence of viral DNA in 66.6% 
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munosuppression raised the question of a possible infec-
tious etiology of this type of cancer.
 In 2008, Feng et al.  [8] identified a new human 
 polyomavirus, designated as Merkel cell polyomavirus 
(MCPyV) based on its detection in human MCC samples 
using a technique known as digital transcriptome sub-
traction. MCPyV is a double-stranded DNA virus of 
5,387 bp that is highly homologous to the murine poly-
omavirus subgroup  [8] and expresses an early region 
(small and large T antigen) and a late region containing 
VP1, VP2 and VP3 open reading frames. It has also 
proved to be monoclonally integrated into the tumor, 
while the already known polyomaviruses BK, JC, WU 
and KI  [9, 10] have been found to be episomal in the re-
lated cancers. This monoclonal pattern of viral integra-
tion suggests a possible role of this virus into MCC carci-
nogenesis. It has also been shown that the MCC harbors 
genes encoding for a truncated form of large T antigen 
(LT) mutations, a process believed to be necessary for 
polyomavirus-mediated carcinogenesis  [11] .
 This study was designed to test the largest number of 
MCC patients so far studied in Switzerland for the pres-
ence of viral DNA using PCR.
 Subjects and Methods 
 Study Design 
 The study included 32 formalin-fixed paraffin-embedded pri-
mary tumor resection specimens from MCC patients obtained 
from pathology and dermatopathology institutes across Switzer-
land between 1994 and 2008. Specimens from control groups were 
also primary tumors. HE and cytokeratin-20 stainings of the se-
lected specimens were repeated to confirm the original diagnosis 
by a board-certified dermatopathologist (K.K.).
 The study was submitted to the ethical committee of Zürich 
(EK No. 860) and the still alive patients gave informed consent to 
use their material for the purposes of the study.
 DNA Extraction 
 Five consecutive 5-  m paraffin sections from each specimen 
were used for DNA extraction. DNA was extracted using a stan-
dard procedure protocol. After deparaffinization the tissues were 
lysed by overnight treatment with proteinase K (56  °  C). DNA was 
purified with phenol and was precipitated with 3  M sodium ace-
tate and absolute ethanol. The pellet was extra washed with 70% 
ethanol to eliminate excess salt. Dried DNA was resuspended in 
60   l of sterile TE and was stored at 4   °   C before it was used for 
PCR. Purified DNA was measured using a Nanodrop 1,000 spec-
trophotometer (Thermoscientific, Wilmington, Del., USA).
 Patient Population 
 The medical records of 9 of the 32 patients included in the 
study were retrospectively reviewed.  The median age of the pa-
tients at the time of diagnosis was 77 years; 45 and 55% of the 
cases were male and female, respectively. One patient had had a 
squamous cell carcinoma (SCC) 2 years before developing MCC 
and one patient was diagnosed with melanoma and SCC also 2 
years before the diagnosis of MCC. The SCC sample from the last 
patient was also included in the study.
 As control groups, we used 8 SCC and 11 normal skin samples 
selected from the archives of the Dermatopathology Institute of 
the University Hospital of Zürich. Control cases were matched 
with the examined MCC patients only according to age, gender 
and localization of the primary lesion.
 Polymerase Chain Reaction 
 DNA integrity was tested with   -globin PCR. PCR was per-
formed with 100–120 ng of genomic DNA using the AmpliTaq 
Gold (Roche Molecular Systems, Basel, Switzerland) in a final vol-
ume of 50   l. For detection of the MCPyV we used 3 primer sets 
(LT1, LT3 and VP1) as published  [8] ; two were directed against the 
LT antigen and one was directed against the VP1 gene. Water was 
used instead of template DNA as negative control.
 Sequence Analysis 
 PCR products of 8 patients were subjected to sequence anal-
ysis. The resulting sequences were compared to the reference 
 sequences of NCBI Entrez Nucleotide Database gb/EU375803 
MCPyV isolated from MCC350 using the Blast program  [12] .
 Results 
 Thirty out of 32 samples revealed a   -globin positive 
product of 268 bp and these samples were included in the 
study. In total, 20 out of 30 MCC samples tested positive 
for the virus with PCR ( fig. 1 ). Five were positive in all 
primer sets, while in 10 cases no viral DNA was amplifi-
able. Out of 30 MCC samples, 6 tested positive for the 
presence of the virus by LT1 (440 bp) primer set, 19 tested 
positive using the LT3 (308 bp) primer set and 16 tested 
m neg 1 2 3 4 pos
298 bp
234 bp
154 bp
308 bp
 Fig. 1. Representative results of the PCR products (308 bp) with 
LT3 primers. m = Molecular weight marker VI; neg = negative 
control (H 2 O); 1–4 = MCC samples; pos = positive control (Merkel 
cell tumor sample obtained from Prof. Axel zur Hausen’s lab). 
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positive using the VP1 (351 bp) primer set ( fig. 2 ). Com-
pared with MCPyV DNA-negative cancers, MCPyV 
DNA-positive cancers tended to be more often located on 
the extremities (65 vs. 40%, p = 0.193, two-sided   2 test), 
which is in accordance with the findings of Sihto et al. in 
a set of North European patients  [13] . PCR-negative con-
trols remained negative in all experiments.
 The virus was not detected in the SCC sample derived 
from one MCC patient. None of our samples of the con-
trol groups (8 SCC and 11 normal skin) were positive for 
the presence of MCPyV.
 The sequenced PCR amplicons showed 96–99% ho-
mology to the NCBI Entrez Nucleotide Database gb/
EU375803 MCPyV isolated from MCC350. We have not 
sequenced the entire viral genome for detection of fur-
ther strain variations.
 Clinical follow-ups of the nine patients for whom we 
received clinical information suggest that there is no sig-
nificant difference regarding the course of disease in 
MCPyV-positive and -negative patients, stratified by tu-
mor stage ( table 1 ).
 Discussion 
 Even though MCC is one of the most aggressive skin 
cancers, with a mortality rate of 33%  [2] , little is known 
about potential signalling mechanisms that drive carci-
nogenesis in MCC  [14] . The high incidence of the recent-
ly described MCPyV in MCC, together with the mono-
clonal integration pattern  [8] and the truncation of LT 
antigen in MCC  [11] shed new light on a potential viral 
carcinogenesis of MCC.
 We demonstrated the presence of viral genome in 
66.6% of our cases with PCR, which is similar to the re-
sults published from other groups  [8, 15–22] . In contrast 
to Feng et al. [8], we used DNA extracted from formalin-
fixed paraffin-embedded specimens. It is known that fix-
ation causes a decrease in amplification efficiency of larg-
er amplicons. Accordingly, we have noticed some differ-
ences in detection of MCPyV using the different primer 
sets. In our lab, LT3 primer proved to be superior for the 
detection of MCPyV, which is also confirmed by other 
groups  [15–17, 21] . Only 6 out of 19 cases tested positive 
for the presence of the virus with primer LT1 (440 bp).
 We were not able to detect any viral DNA in our con-
trol groups, neither in SCC nor in normal skin. Kassem 
et al.  [23] recently demonstrated the presence of viral 
DNA in 32% of sporadic non-melanoma skin cancers. 
They also showed that MCPyV was more frequently 
found in non-melanoma skin cancers of immunosup-
pressed patients compared to immunocompetent pa-
tients. This discrepancy may be due to the higher num-
bers of cases in their study than in ours.
 Andres et al. reported no relevant association of 
MCPyV with seborrheic keratosis, basal cell carcinoma, 
and lentigo maligna melanoma in an age- and sex-
matched non-MCC population when the virus was found 
in 6% (2/33) of all the investigated non-MCC skin tumors 
 [24] .
 In the one patient in our set suffering from a MCPyV-
positive MCC and, previously, from an SCC, we did not 
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 Fig. 2. MCPyV PCR results using the three different primer sets 
LT1, LT3, VP1, and overall positivity/negativity combining all the 
results from the three primer sets. 
Table 1.  Patient characteristics and comparison of tumor stage 
between MCPyV-positive and -negative patients
Patient
ID
Gen-
der
Age at
diag-
nosis
MCPyV Stage
at diag-
nosis
Stage at
date last
seen
Follow-up
months
1 f 72 neg stage I stage II 16.4
2 m 76 neg stage I stage III 43.2
3 f 73 neg stage I stage I 84
4 m 71 neg stage I stage I 77.3
5 f 75 pos stage I stage I 32.2
6 f 82 pos stage I stage I 16
7 m 83 pos stage II stage II 29.4
8 m 79 pos stage I stage II 21.2
9 f 84 pos stage I stage I 8.33
f = Female; m = male; pos = positive; neg = negative.
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find the virus in the SCC. This may be due to a specific 
targeting of Merkel cells by the virus, or to a viral infec-
tion after the excision of the SCC. Foulongne et al., on the 
other hand, detected viral DNA in 71% of non-tumoral 
skin samples of patients with MCC. However, the MCPyV 
DNA levels appeared to be higher in MCC tumour tissue 
than in nontumoral skin in their set of patients  [25] . Fur-
thermore, based on the presence of LT-truncated MCPyV 
in approximately 15% of SCCs from immunocompetents 
in their patient set, Dworkin et al.  [26] even suggested a 
causative role of MCPyV in SCC, in analogy to Shuda et 
al.  [11] who showed that the LT antigen derived from 
MCC tumor areas is truncated and lacks the LT MCPyV 
helicase. This in turn leads to replication incompetence 
in the virus, thus suggesting an early precancerous inte-
gration of the virus into the genome.
 Recently, a monoclonal antibody CM2B4 was devel-
oped against a peptide fragment of the MCV T antigen 
exon 2  [27] . The antibody was immunoreactive with the 
majority of the PCR-positive tumors (77%)  [28] and 
showed also high specificity. Immunohistochemistry as 
a relatively cheap routine procedure may become the 
method of detection of MCPyV, but the sensitivity issues 
will have to be addressed.
 In summary, we found MCPyV in 66.6% of our Swiss 
MCC patient set. This number is similar to the reported 
incidences in two American MCC patient sets (69%  [20] 
and 80%  [8] ) and the European experience (85%  [18] and 
79.8%  [13] ), but higher than in an Australian patient set 
(24%  [20] ). It has been speculated that the differences in 
the virus prevalence may be due to a higher contribution 
of UV in the pathogenesis of MCC in Australian patients, 
or to the presence of virus that remained undetected in 
the assays which were applied, but not to the quality of 
DNA used in the assays, as the PCR controls were consid-
ered excellent in the Australian set with the low detection 
rate of MCPyV  [20] .
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